ISSN: 2578-4625
Authors: Ngatali CFS*, Boumba LMA, Mabiala Y, Moukassa D and Nkoua Mbon JB
Introduction: Breast cancer is the leading cancer and the leading cause of cancer death in women worldwide. While the 5-year survival of patients with local breast cancer varies around 98.8%, this survival rate drops to around 26.3% for metastatic patients. The objective of this study was to determine the survival of patients with breast cancer in resourcelimited settings. Patients and Methods: It was a cross-sectional descriptive study performed in the cancer ward at Pointe Noire General Hospital from 1 January 2013 to 31 December 2018, for duration of 6 years. 70 records of patients over 18 years of age with histological evidence and an extension assessment involving a thoraco-abdominal CT or chest X-ray and / or abdominal ultrasound. The treatments received included: surgery, chemotherapy, radiotherapy and hormone therapy targeted therapy. The variables studied were: age, level of education, delay of consultation, histological type, histological grade, stage of extension, type of treatment and survival. Survival was calculated by Kaplan Meier method. The chi-square test was used to search for a correlation between the variables. Results: The average age was 51±12 years old. The extremes were 27 years and 79 years old. The most represented level of education was the primary level in 63 % of cases. The most represented stage was locoregional stage in 57 % of cases and metastatic stage in 33 % of cases. The most represented histological type was invasive ductal carcinoma in 97 % of cases. The most represented histological grade was Scharff grade III Richardson bloom in 68 % of cases. The treatment Anthracycline-based chemotherapy was more used in 74 % of cases. Surgery was used in 49 % of cases; radiation therapy was use in 26 %. Bivariate analysis revealed the lack of correlation between delay to consultation and stage of extension p˃0.05. There was no correlation between age and the stage of extension, p <0.05. The mean patient follow-up time was 22 ± 15.45 months. The overall survival was 39 months. The median survival of local, locoregional and metastatic stage was respectively 25 months, 29 months, 29 months, P> 0.05. Patients treated with anthracyclines were greater than that of patients treated with taxanes in combination was 48 months, p˂ 0.05, results significant. Research. Conclusion: Breast cancer remains an incurable disease, its survival remains low despite diagnostic and therapeutic advances that remain difficult to access for our resource-poor developing countries. Patients are treated with conventional surgery, chemotherapy (anthracyclines and taxanes), radiation therapy, hormone therapy and targeted therapy are not used in optimal way in our context.
Keywords: Breast Cancer; Survival; Black Point
